Company Filing History:
2 out of 314 
1 out of 40 
1 out of 318 
Years Active: 1985-1999
Title: Nobuhiko Katunuma: Innovator in Alzheimer's Research
Introduction
Nobuhiko Katunuma is a prominent inventor based in Tokushima, Japan. He has made significant contributions to the field of pharmaceutical sciences, particularly in the treatment of Alzheimer's disease. With a total of 4 patents to his name, his work has garnered attention for its innovative approaches to managing neurodegenerative conditions.
Latest Patents
Katunuma's latest patents include the development of an epoxysuccinamide derivative or salt thereof, along with a medicine comprising methods of treatment using Alzheimer's amyloid polypeptide derivatives. His research also focuses on pharmaceutical compositions containing a 57 amino acid protease inhibitor known as A4i, which is associated with Alzheimer's disease. These compositions have shown promise in inhibiting various proteases linked to diseases, providing potential therapeutic avenues for managing conditions related to protease release in the circulatory system.
Career Highlights
Throughout his career, Katunuma has worked with notable companies such as Taisho Pharmaceutical Co., Ltd. and Scios Nova, Inc. His expertise in protease inhibitors and their applications in treating Alzheimer's disease has positioned him as a key figure in pharmaceutical innovation.
Collaborations
Katunuma has collaborated with esteemed colleagues, including Barbara Cordell and James W. Schilling, Jr. These partnerships have furthered his research and contributed to advancements in the field of Alzheimer's treatment.
Conclusion
Nobuhiko Katunuma's work exemplifies the intersection of innovation and healthcare. His contributions to Alzheimer's research through his patents and collaborations highlight the importance of continued exploration in the pharmaceutical sciences.